Safety of cinacalcet in children and adolescents with chronic kidney disease-mineral bone disorder: systematic review and proportional meta-analysis of case series
Conclusions and implications of key findingsIf used in the pediatric population, the calcimimetic cinacalcet should be carefully monitored for serum calcium levels and attention to possible adverse events, especially in children under 50 months.Systematic review registration number (PROSPERO register)CRD42019132809.
Source: International Urology and Nephrology - Category: Urology & Nephrology Source Type: research
More News: Calcium | Children | Chronic Kidney Disease | Clinical Trials | Hormones | Orthopaedics | Pediatrics | Phosphorus | Science | Sensipar | Study | Urology & Nephrology | Vitamin D | Vitamins